The mission of our clinical research is to foster discoveries in the novel therapies of inflammatory bowel diseases, gastrointestinal and pancreatic cancer, hepatitis, and other gastrointestinal disorders. Our doctors are committed to providing the best care and management of diseases while testing cutting-edge therapies.

Back to full list of clinical trials

Ongoing clinical trials for HIV and hepatitis C co-infection: Actively recruiting


Condition:

HCV/HIV co-infection

Study title:

A5294: A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects

Description of study:

This study will evaluate the safety, efficacy and tolerability of the drug boceprevir in combination with Peginterferon and Ribavirin for the treatment of HCV in co-infected patients

Basic eligibility criteria:

Adults coinfected with HCV genotype 1 and HIV

Principal Investigator:

Arthur Kim, MD

Contact:

Teri Flynn, RN, MSN, ANP; 617-726-5596


Ongoing clinical trials for HIV and hepatitis C co-infection: No longer recruiting


Study title:

Open Label Study of Safety and Efficacy with BMS-790052 plus PEG/RBV in Previously Untreated HCV Patients Co-infected with HIV and HCV

Description of study:

This study will evaluate the safety, efficacy and tolerability of the drug BMS-790052 in combination with Peginterferon and Ribavirin for the treatment of HCV in co-infected patients.

Principal Investigator:

Arthur Kim, MD